Cao Guo-Dong, Chen Bo, Xiong Mao-Ming
Anhui Medical University, Hefei, Anhui, China.
Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
PLoS One. 2017 Jun 1;12(6):e0176431. doi: 10.1371/journal.pone.0176431. eCollection 2017.
Metastasis-associated protein 1 (MTA1) is a transcriptional regulator and significantly associated with prognosis of patients with cancer. However, its role as a potential prognostic marker in digestive tract cancer (DTC) is controversial. In this study, a meta-analysis was conducted to evaluate the MTA1 expression as a predictor of clinicopathology and survival of patients with DTC.
We searched PubMed, Ovid, Web of Science and Cochrane databases using multiple search strategies for eligible studies. STATA 11.0 software was used to pool the data and analyze the association, odds ratios (ORs) and 95% confidence intervals (CIs) were used to measure the strength of the association. Furthermore, the Newcastle-Ottawa scale was used to evaluate the quality of eligible studies.
MTA1 overexpression was strongly associated with depth of invasion (OR = 1.88, 95%CI: 1.05-3.37, P = 0.03), lymph node metastasis (OR = 2.30, 95%CI: 1.76-3.01, P<0.001), vascular invasion (OR = 2.02, 95%CI: 1.40-2.91, P<0.001) and TNM stage (OR = 2.78, 95%CI: 1.63-4.74, P<0.001), and was related to 1- (RR = 1.84, 95%CI: 1.18-2.89, P = 0.008), 3- (RR = 1.74, 95%CI: 1.32-2.30, P<0.001) and 5-year (RR = 1.64, 95%CI: 1.18-2.27, P = 0.003) OS. Further, MTA1 was associated with 1- (RR = 4.16, 95%CI: 1.35-12.81, P = 0.01), 3- (RR = 1.90, 95%CI: 1.02-3.53, P = 0.04) and 5- (RR = 2.17, 95%CI: 1.41-3.32, P<0.001) year DFS. In subgroup analyses based on study quality and tumor type, MTA1 overexpression was obviously related to clinical parameters, such as lymph node metastasis and TNM stage, and was also associated with prognosis of patients with gastrointestinal or esophageal cancer.
MTA1 expression is strongly correlated with metastasis-related variables, and represents a promising prognostic factor in DTC.
转移相关蛋白1(MTA1)是一种转录调节因子,与癌症患者的预后显著相关。然而,其作为消化道癌(DTC)潜在预后标志物的作用存在争议。本研究进行了一项荟萃分析,以评估MTA1表达作为DTC患者临床病理和生存的预测指标。
我们使用多种检索策略在PubMed、Ovid、科学网和Cochrane数据库中检索符合条件的研究。使用STATA 11.0软件汇总数据并分析相关性,采用比值比(OR)和95%置信区间(CI)来衡量关联强度。此外,使用纽卡斯尔-渥太华量表评估符合条件研究的质量。
MTA1过表达与浸润深度(OR = 1.88,95%CI:1.05 - 3.37,P = 0.03)、淋巴结转移(OR = 2.30,95%CI:1.76 - 3.01,P<0.001)、血管侵犯(OR = 2.02,95%CI:1.40 - 2.91,P<0.001)和TNM分期(OR = 2.78,95%CI:1.63 - 4.74,P<0.001)密切相关,并且与1年(RR = 1.84,95%CI:1.18 - 2.89,P = 0.008)、3年(RR = 1.74,95%CI:1.32 - 2.30,P<0.001)和5年(RR = 1.64,95%CI:1.18 - 2.27,P = 0.003)总生存期相关。此外,MTA1与1年(RR = 4.16,95%CI:1.35 - 12.81,P = 0.01)、3年(RR = 1.90,95%CI:1.02 - 3.53,P = 0.04)和5年(RR = 2.17,95%CI:1.41 - 3.32,P<0.001)无病生存期相关。在基于研究质量和肿瘤类型的亚组分析中,MTA1过表达与临床参数如淋巴结转移和TNM分期明显相关,并且也与胃肠道或食管癌患者的预后相关。
MTA1表达与转移相关变量密切相关,是DTC中有前景的预后因素。